Zhipu AI and Iluvatar CoreX Semiconductor shares surged Thursday following separate secondary share placements to raise billions of Hong Kong dollars for hardware and research. Investor appetite remained robust despite expired lock-up periods, showcasing a common strategy for Chinese tech firms to secure funding post-IPO.
Zhipu AI has launched ZCode, a tool for developers to build autonomous coding assistants, intensifying its competition with US firm Anthropic. The launch includes promotions like increased data quotas and free tokens for new users.
The US tech containment strategy, exemplified by Anthropic's model shutdown, is driving market realignment and boosting Chinese AI firms like Zhipu AI. Amid this US-China AI decoupling, Hong Kong is positioned to develop a unique regulatory framework and bridge diverging AI ecosystems.
Zhipu AI's market capitalization exceeded $128 billion on Monday, driven by investor optimism following the release of its new GLM-5.2 model. The model ranks second globally for front-end web development tasks.
Hong Kong stocks face potential price pressure and uncertainty as lock-up periods for IPO shares expire, with historical data suggesting median declines post-expiry. Investors are advised to carefully parse metrics amid limited AI exposure.
Zhipu AI released GLM-5.2 with a 1-million-token context window, significantly undercutting Western AI models on price. The company's Hong Kong-listed stock surged by up to 48% following the announcement.
Zhipu (Knowledge Atlas Technology) surpasses MiniMax in market capitalization, attributed to stronger AI capabilities, looming share unlocks, and investor preference for enterprise-focused businesses.
AI developers MiniMax Group and Knowledge Atlas Technology are listing in Hong Kong before pursuing mainland China stock offerings. This strategy aims to establish international valuations and attract global investors.
Chinese AI firms MiniMax Group and Zhipu AI will be added to the Hang Seng Tech Index on June 5, increasing its constituents to 93. Hansoh Pharmaceutical and Akeso will join the Hang Seng China Enterprises Index. Investor sentiment has been affected by the US-Israel war on Iran and weak results from Chinese tech platforms.
